AHR and cancer: While not yet approved for cancer therapy, the AhR agonist tapinarof (98) is in clinical trials for atopic dermatitis and plaque psoriasis (NCT05142774, NCT05680740) and could potentially be tested for the treatment of dermatological malignancies in the future.